Skip to main content

Advertisement

Table 2 Univariate analysis for survival

From: Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases

Factors N Survival rate (%) Mean survival (month) Median survival (month) P value
1 year 2 years 3 years 5 years 7 years 10 years
Radiotherapy on metastasis sites   0.817
 With 35 97.14 82.86 62.61 38.76 25.83 13.84 66.1 54  
 Without 69 92.75 73.91 54.66 36.63 26.03 17.85 59.4 46  
Chemotherapy   0.875
 With 19 94.74 78.95 68.42 38.6 20.58 20.58 62.3 53  
 Without 85 94.12 76.47 54.76 36.82 26.48 15.61 65.2 46  
Gleason scores when diagnosed as PCa   0.564
 2–4 1 100.00 100.00 100.00 100.00 0.00 0.00 79.0 79  
 5–7 31 100.00 90.32 57.45 42.79 28.53 23.77 75.5 45  
 8–10 72 91.67 70.83 56.66 33.80 24.96 11.88 55.0 49  
PSA when bone metastases occurred   0.692
 <4 ng ml−1 7 85.71 71.43 71.43 42.86 28.57 14.29 61.4 54  
 4–20 ng ml−1 10 90.00 80.00 70.00 45.00 45.00 22.50 78.6 58  
 >20 ng ml−1 87 95.40 77.01 54.71 35.74 23.36 15.73 58.1 45  
ALP when bone metastases occurred   0.020
 <150 U I−1 51 96.09 82.35 64.4 45.6 33.74 24.78 78.6 57  
 ≥150 U I−1 53 82.45 71.70 50.8 28.16 15.08 0.00 46.7 40  
The number of bone metastases   0.006
 Single 18 100 94.44 77.78 66.67 49.38 39.51 104.8 84  
 Multiple 86 93.02 73.26 53.07 30.46 20.35 10.97 53.1 40  
Regional lymph node metastases   0.011
 With 21 90.48 57.14 28.57 21.43 21.43 10.71 71.0 54  
 Without 83 95.18 81.93 64.82 41.60 27.51 17.59 42.9 31  
Metastases when bone metastases occurred   0.588
 Without 72 98.61 80.56 59.35 38.29 25.54 17.69 69.5 52  
 Neighbouring organsa 23 78.26 65.22 51.51 32.78 27.31 47.9 43  
 Distant organsb 9 100.00 77.78 55.56 41.67 44.3 53  
  1. ALP alkaline phosphatase; PSA prostate-specific antigen
  2. a Defined as an organ around with prostate, such as the bladder, spermatophores, urethra and rectum
  3. b Defined as brain, lung and liver metastases